- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Case Reports in Medicine
Volume 2010 (2010), Article ID 262706, 5 pages
A Case of Supplement-Induced Hepatotoxicity
1Department of Medicine, Madigan Army Medical Center, Tacoma, WA 98431, USA
2Gastroenterology Service, Department of Medicine, Madigan Army Medical Center, Tacoma, WA 98431, USA
Received 26 April 2010; Revised 29 June 2010; Accepted 15 July 2010
Academic Editor: Anne M. Larson
Copyright © 2010 Fong-Kuei Frank Cheng and Peter Dunaway. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A 45-year-old Caucasian male presented with a two-week history of jaundice and right-upper quadrant (RUQ) abdominal pain. Transaminases and biliary enzymes were markedly elevated with hyperferritinemia and mildly elevated INR. Imaging tests showed no significant abnormality. He denied prescription or over-the-counter (OTC) medication use, but he had been taking at least 9 dietary supplements for 12 months. Other causes of liver disease were excluded. His supplements were discontinued, and his liver-associated enzymes significantly markedly improved over the next 6 weeks and remained normal after one year suggesting supplement-induced hepatotoxicity. Due to the number of supplements, no specific agent could be identified as the primary cause of his liver injury. This case illustrates the importance of inquiring and educating patients of the potential harmful risks of over-the-counter medications and supplements.
Over-the-counter (OTC) supplement use has increased in the United States over the past decade, and sources estimate that consumers can now choose from over 29,000 products . Dietary supplement-related hepatotoxicity, an underreported condition, is usually associated with minor liver-associated enzyme elevations . We describe a case of severe hepatotoxicity with jaundice and mild synthetic dysfunction in a patient taking multiple dietary supplements.
A previously healthy 45-year-old white male complained of dull aching RUQ pain associated with nausea two weeks prior to his initial presentation to primary care. The pain was constant, nonradiating, and most intense two hours after meals. The pain was followed by icterus, jaundice, and generalized weakness, which progressively worsened over the week. He had secondary anorexia over the symptomatic period and had lost 20 lbs over the previous two months. He denied pruritus, easy bleeding/bruising, melena, abdominal distention, mental status changes, increased somnolence, diarrhea, or fever.
He initially reported taking only a few daily supplements over the previous 12 months for the promotion of general health. However, on further questioning, he admitted using nine different products many of which had been started one-to-four months prior to his symptom onset (Table 1). He had stopped all supplements intake after the development of his symptoms.
Additional risk factors for secondary causes of liver disease were negative to include a history of viral hepatitis, blood product transfusion, intravenous drug abuse, multiple sexual partners, and prescription medications. He consumed two-to-three mixed drinks on social occasions and was not a habitual alcohol consumer. He denied acetaminophen use or the ingestion of wild mushrooms. He recently vacationed with his wife in Puerto Rico three months prior to presentation but denied any additional foreign travel. He had no family history of liver disease and denied any ill contacts.
His physical examination was only notable for jaundice, scleral icterus, and mild RUQ abdominal tenderness on deep palpation. Significant presentation labs are as follows: ALT 6409 U/l, AST 3505 U/l, alkaline phosphatase 269 U/L, total bilirubin 31 mg/uL, conjugated bilirubin 18 mg/dL, prothrombin time 12.6 sec, and INR 1.2. Iron studies were ferritin 2641 ng/mL, fasting iron 235 ug/dL, TIBC 290 ug/dL, and % transferrin sat 81%. CBC was normal without eosinophilia. Serum acetaminophen level was immeasurable as the severe hyperbilirubinemia interfered with the assay. The patient did not have any baseline liver enzymes for comparison. RUQ ultrasound and CT abdomen revealed mild diffuse thickening of the gallbladder without cholelithiasis or intra/extrahepatic ductal dilatation. The pancreas, liver, portal veins, and spleen were otherwise normal.
The workup for other causes of liver disease includes IgM anti-HAV, IgM anti-HBc, HbsAg, anti-HCV, ceruloplasmin, mitochondrial antibody, ANA, SPEP, and anti-LKM which were negative/normal except for the presence of one heterozygous copy of the H63D mutation in the HFE gene and a highly positive smooth muscle antibody of 32 (>30 highly positive). Liver histopathology revealed mild periportal and intraparenchymal chronic inflammation, including plasma cells, with focal areas of acute inflammation and patchy hepatocyte necrosis with moderately increased iron storage (Iron liver dry weight 321 ug/g (400–2200) hepatic iron index 0.1 umoL/g/yr (<1.0)) (Figure 1). Copper studies of liver biopsy were not performed.
The liver biopsy was secondarily reviewed by the Armed Forces Institute of Pathology that reported widespread zone 3 (centrilobular) confluent necrosis and stromal collapse with patchy portal inflammation and considerable bile stasis. Their interpretation of the combined cholestatic and hepatocellular injury pattern was consistent with drug/supplement-related hepatotoxicity. The findings were not consistent with autoimmune hepatitis. At 6 weeks, the patient’s symptoms had resolved. Repeat liver-associated enzymes had nearly normalized (ALT-135 U/L and total bilirubin-1.4 mg/uL) and iron studies showed a % iron saturation of 52% and serum ferritin of 196 ng/ml (Figure 2). At one year, his liver enzymes were completely normal. To date, the patient remains asymptomatic and continues to avoid OTC supplements.
Approximately 65% of the US population reports use of complementary and alternative medical (CAM) therapies. In 1997, US consumers spent $46 billion on CAM therapies and dietary supplements. Women and non-Hispanic whites more frequently use alternative medicines compared to males and other racial groups, respectively . While many explanations have been offered for increased use of CAM therapy, users generally view natural products as superior and innocuous compared to traditional medications. These consumers also often seek alternative treatments when they are not satisfied with conventional treatment .
In 1994, the Dietary Supplement Health and Education Act expanded the responsibilities of the Food and Drug Administration (FDA) to include monitoring safety and product information of CAM therapies . Enforcement of this regulation has proved problematic, as manufacturers are still not required to register for FDA approval or prove a product’s safety prior to marketing . Content labeling and product consistency remain variable, and adverse effects from these products are likely underreported.
Hepatotoxicity is common with both CAM and conventional medication therapies, due to the liver’s primary role in drug metabolism . Medication-induced liver injury is often grouped into types of injury based on biochemical and histological abnormalities, and certain medications have been classically associated with specific injury patterns . Our patient manifested a mixed liver injury pattern. Our case is interesting in that our patient’s transaminases were three-to-six times higher than those of other cases reported in the medical literature . The clinical and laboratory presentation represents severe hepatotoxicity with mild synthetic dysfunction and rapid resolution, while many cases in literature progress to acute liver failure.
Our patient was taking nine different supplements which comprised of over thirty individual ingredients (Tables 1 and 2). He was also taking several supplements which contained no ingredient description. All available ingredients were reviewed for potential harm using the original product’s manufacturer website, the consumer reports from the US Food and Drug Administration, and annual reports from the American Association of Poison Control Center. Table 3 lists common herbal remedies associated with hepatotoxicity [7, 8]. When comparing the patient’s list of ingredients to the common toxins causing hepatotoxicity, potential offending agents include vitamin A, copper, iron, and niacin. Unfortunately a specific contributing source could not be ascertained, due to the large number of supplements involved and the unknown ingredients of a few of the supplements. Our patient’s markedly elevated ferritin and antismooth muscle antibodies were most likely due to the supplement-induced acute liver injury. His increased % iron saturation, interestingly, is secondary to his H63D heterozygous mutation as his ferritin was normalized in followup but the increased % iron saturation persisted. The low hepatic iron weight and hepatic iron index ruled out hemochromatosis. Autoimmune hepatitis was ruled out clinically and confirmed by the normalization of his liver enzymes.
Treatment for supplement-induced hepatotoxicity consists of prompt cessation of all supplement use. The development of any encephalopathy or worsening of coagulopathy requires an immediate referral to a medical center with a liver transplantation service . There are no confirmatory tests; however, appropriate evaluation to exclude other underlying hereditary or acquired liver disease is prudent. Clinical improvement occurs in most cases after discontinuance of offending agent, but liver injury may worsen or follow a protracted recovery course of weeks or months . If patients develop acute fulminant hepatic failure, important prognostic indicators include the degree of encephalopathy, the patient’s age, prothrombin time, and the cause of acute liver failure . Given the absence of encephalopathy, prompt normalization of his initial mild protime elevation, and gradual recovery within weeks after discontinuing his supplements, liver transplantation was not considered in our patient. This case emphasizes the importance of recognizing the widespread use of over-the-counter supplements and herbal remedies. Health care providers should inform their patients about the potentially harmful risks of over-the-counter supplement use, particularly hepatotoxicity. Providers should also be vigilant about reporting any suspected supplement-related hepatotoxicity to the FDA immediately.
- D. M. Eisenberg, R. B. Davis, S. L. Ettner, S. Appel, S. Wilkey, M. Van Rompay, and R. C. Kessler, “Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey,” Journal of the American Medical Association, vol. 280, no. 18, pp. 1569–1575, 1998.
- A. J. Pugh, A. J. Barve, K. Falkner, M. Patel, and C. J. McClain, “Drug-induced hepatotoxicity or drug-induced liver injury,” Clinics in Liver Disease, vol. 13, no. 2, pp. 277–294, 2009.
- D. Larrey, “Hepatotoxicity of herbal remedies,” Journal of Hepatology, vol. 26, supplement 1, pp. 47–51, 1997.
- US Food and Drug Administration. Center for Food Safety and Applied Nutrition, “Dietary Supplements,” http://www.fda.gov/Food/DietarySupplements/default.htm.
- W. M. Lee, “Drug-induced hepatotoxicity,” The New England Journal of Medicine, vol. 349, no. 5, pp. 474–485, 2003.
- R. M. Bashir and J. H. Lewis, “Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders,” Gastroenterology Clinics of North America, vol. 24, no. 4, pp. 937–967, 1995.
- M. W. Lai, W. Klein-Schwartz, G. C. Rodgers, J. Y. Abrams, D. A. Haber, A. C. Bronstein, and K. M. Wruk, “2005 Annual report of the American Association of Poison Control Centers' national poisoning and exposure database,” Clinical Toxicology, vol. 44, no. 6-7, pp. 803–932, 2006.
- G. Wolf, “A history of vitamin A and retinoids,” The FASEB Journal, vol. 10, no. 9, pp. 1102–1107, 1996.
- J. Polson and W. M. Lee, “AASLD position paper: the management of acute liver failure,” Hepatology, vol. 41, no. 5, pp. 1179–1197, 2005.